1 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Iain Bressendorff: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD Dialysate calcium 1.50 mmol/L - Secondary Hyperparathyroidism, End-stage Kidney Disease | Phase 2 | Unknown | Iain Bressendorff | 48 | 2024-08-01 | 2024-05-03 |
| Circulating Factors in Nephrotic Syndrome Observation - Nephrotic Syndrome, Membranous Nephropathy | Not yet recruiting | Iain Bressendorff | 104 | 2024-04-01 | 2024-03-19 | |
| Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib - Diabetic Kidney Disease | Phase 2 | Terminated | Iain Bressendorff | 1 | 2023-08-01 | 2024-09-25 |
| The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis Dialysate magnesium (1.0 mmol/L), Dialysate magnesium (0.5 mmol/L) - Endstage Renal Disease | Phase 2 | Completed | Iain Bressendorff | 59 | 2016-12-01 | 2018-06-06 |
Chronic Kidney Disease-Mineral and Bone Disorder (1) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · Hyperparathyroidism, Secondary (1) · Kidney Failure, Chronic (1) · Nephrosis, Lipoid (1) · Nephrotic Syndrome (1)
Angiotensin-Converting Enzyme Inhibitors (1) · Observation (1) · Pentoxifylline (1) · baricitinib (1) · finerenone (1) · semaglutide (1)
Denmark (2)